Latest News

The FDA approves obinutuzumab (Gazyva; Genentech, Roche) for lupus nephritis, offering a new treatment option with improved renal outcomes for patients.

Pharmacists play a vital role in managing respiratory virus season by providing vaccinations, counseling, and recommending effective treatments for patients.

Long-term findings from the REASSURE study confirm Radium-223’s acceptable hematologic safety profile and reinforce the importance of early use alongside bone-protecting agents to minimize fracture risk and optimize outcomes.

Personalized cancer vaccines target tumor heterogeneity, enhancing immune responses and improving treatment outcomes in diverse cancer types.

Experts at ESMO 2025 highlight antibody-drug conjugates in HER2-positive metastatic breast cancer treatment.

Emerging biomarkers and targeted therapies are reshaping the landscape of lung cancer treatment and drug development.

Advances in targeted therapies, combination approaches, and novel treatment strategies are shaping the management of drug-resistant lung cancer.

Insights from ESMO 2025 highlight advancements in non-small cell lung cancer treatment, focusing on novel therapies and molecular diagnostics.

Adjuvant abemaciclib plus endocrine therapy significantly enhances overall survival in high-risk HR-positive HER2-negative breast cancer.

Durvalumab combined with FLOT shows significant survival benefits for patients with resectable gastroesophageal junction cancer, regardless of PD-L1 status.

Students can better balance parenthood, academics, and self-care with planning, resilience, and strong support systems.

Novel mechanism offers hope for improved tolerability and efficacy in patients facing resistance or long-term toxicity with existing TKIs.

An index of total cholesterol, high-density lipoprotein (HDL), and fasting glucose levels was found to indicate the prevalence of type 2 diabetes in a nationally representative US cohort.

The expanded indications now include adolescents with hidradenitis suppurativa aged 12 and older and pediatrics with uveitis aged 2 and older.

Revised recommendations include new thresholds for initiating antihypertensive therapy using the PREVENT equation.

Nivolumab plus chemotherapy and ipilimumab show significant long-term survival benefits for advanced esophageal squamous cell carcinoma.

Glofitamab-GemOx improves survival in transplant-ineligible patients with R/R DLBCL.

The mean time intervals between injection and complete retinal vascularization were similar between the biosimilar and its reference product.

Three targeted inhibitors offer new strategies for HR-positive, HER2-negative breast cancer with PIK3CA mutations.